Last updated: February 16, 2026
Product Overview
NDC 00037-6010 corresponds to Xarelto (rivaroxaban), an oral anticoagulant developed by Bayer and marketed by Johnson & Johnson. It is indicated for prevention of stroke in non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and reduction of thrombotic events post-orthopedic surgeries.
Market Landscape
Xarelto's global sales predominantly target the anticoagulant market, which was valued at approximately $14 billion in 2022 [1]. The drug competes primarily with direct oral anticoagulants (DOACs) like Pradaxa (dabigatran), Eliquis (apixaban), and Savaysa (edoxaban).
Market Penetration and Usage Trends
- As of 2023, Xarelto maintains a leading position in the U.S. DOAC market with an estimated 35% share [2].
- Increase in atrial fibrillation prevalence and expanded indications have supported growing prescriptions.
- The global anticoagulant market is expected to grow at a compound annual growth rate (CAGR) of roughly 7% through 2028 [1].
Pricing Dynamics
- Current Wholesale Price: Approximately $10–$15 per tablet, depending on dosage and region [3].
- Average Monthly Cost: Ranges from $300 to $450 across the U.S., translating annually to roughly $3,600–$5,400 per patient.
- Reimbursement Trends: Payers increasingly favor DOACs over warfarin due to ease of use; however, high out-of-pocket costs limit adherence for some populations.
Projected Price Trends
- Generic Entry:
- Patent expiry anticipated in mid-2026 in the U.S. [4].
- First generics could reduce price by 50–70%.
- Market Competition:
- As cheaper alternatives enter, branded pricing may decline to remain competitive, especially in cost-sensitive segments [$2–$4 per tablet] post-generic.
- Reimbursement Policies:
- Insurers pushing for formulary prioritization of generics may further pressure prices downward.
- Pricing in Emerging Markets:
- Lower per-unit pricing expected, with projected reductions of 40–60% relative to U.S. prices due to economic factors and healthcare infrastructure disparities.
Future Market Drivers
- Wider adoption in developing countries.
- New indications or combination therapies.
- Biosimilars and generics.
- Potential price regulation and negotiation policies, particularly in Europe and North America.
| Summary of Price Projections |
Year |
Scenario |
Estimated Price per Tablet |
Notes |
| 2024 |
Baseline |
$10–$15 |
Current pricing; post patent expiry preparations begin |
| 2025 |
Pre-generic |
$10–$15 |
No major patent challenges yet |
| 2026 |
Patent expiry |
$2–$4 |
Generics enter the market, significantly reducing prices |
| 2027–2028 |
Post-generic |
$2–$4 |
Market stabilizes around generic competition |
Key Takeaways
- NDC 00037-6010 corresponds to Xarelto, a leading DOAC in a growing anticoagulant market.
- The market is poised for a significant price decline following patent expiration in mid-2026, with generic competition expected to reduce prices substantially.
- Current reimbursement trends favor the use of DOACs, but high medication costs influence adherence.
- Price reductions in emerging markets will be more aggressive, influenced by economic and regulatory factors.
- The combination of increased global demand and patent expiry will shape the next phase in pricing and market dynamics.
FAQs
1. When will generic rivaroxaban likely become available?
Patent expiration in the U.S. is projected for mid-2026, with generics entering shortly thereafter.
2. What factors could influence the timing of price reductions?
Regulatory approval, patent litigation, manufacturing capacity, and payer policies.
3. How does Xarelto compare to competitors in market share?
It holds approximately 35% in the U.S. DOAC market, trailing Eliquis but ahead of Pradaxa and Savaysa.
4. Are there any upcoming patent litigations that might delay generics?
Historically, patent litigations can extend exclusivity; current disputes are ongoing but unlikely to delay issuance past 2026.
5. How might new indications or formulations affect future pricing?
Additional indications could sustain higher prices longer; novel formulations might command premium pricing.
References
[1] Mordor Intelligence. "Anticoagulants Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023–2028)."
[2] IQVIA. "U.S. Prescription Data, 2023."
[3] GoodRx. "Xarelto (rivaroxaban) prices and savings."
[4] FDA. "Patent and exclusivity database, 2023."
